Ziopharm Oncology Inc. (NASDAQ:ZIOP) was the target of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 37,427,735 shares, a decrease of 3.8% from the August 31st total of 38,909,971 shares. Approximately 31.7% of the company’s stock are sold short. Based on an average daily trading volume, of 1,734,211 shares, the days-to-cover ratio is currently 21.6 days.
Shares of Ziopharm Oncology (NASDAQ:ZIOP) opened at 5.63 on Friday. The stock’s 50 day moving average is $5.49 and its 200-day moving average is $6.40. Ziopharm Oncology has a 52 week low of $4.45 and a 52 week high of $14.93. The firm’s market cap is $734.69 million.
Ziopharm Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by $0.90. The business earned $1.70 million during the quarter, compared to analyst estimates of $1.52 million. Ziopharm Oncology had a negative net margin of 2,292.26% and a negative return on equity of 100.01%. The business’s revenue for the quarter was up 525.0% compared to the same quarter last year. During the same period last year, the company earned ($0.11) earnings per share. On average, equities analysts predict that Ziopharm Oncology will post ($1.34) EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in the stock. Fox Run Management L.L.C. acquired a new position in shares of Ziopharm Oncology during the second quarter worth about $133,000. Stratos Wealth Partners LTD. acquired a new position in shares of Ziopharm Oncology during the first quarter worth about $102,000. BlackRock Institutional Trust Company N.A. increased its position in shares of Ziopharm Oncology by 0.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 3,045,989 shares of the biotechnology company’s stock worth $22,601,000 after buying an additional 17,982 shares during the period. Brown Advisory Inc. acquired a new position in shares of Ziopharm Oncology during the second quarter worth about $1,166,000. Finally, California State Teachers Retirement System increased its position in shares of Ziopharm Oncology by 4.9% in the second quarter. California State Teachers Retirement System now owns 254,849 shares of the biotechnology company’s stock worth $1,399,000 after buying an additional 11,934 shares during the period. 44.95% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts recently commented on the stock. Zacks Investment Research raised shares of Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a research report on Wednesday, July 27th. Griffin Securities reissued a “buy” rating and set a $21.00 price target on shares of Ziopharm Oncology in a research report on Friday, July 1st. Mizuho reissued a “neutral” rating and set a $5.00 price target (down from $7.00) on shares of Ziopharm Oncology in a research report on Monday, July 18th. Finally, Wells Fargo & Co. reissued an “underperform” rating on shares of Ziopharm Oncology in a research report on Friday, July 15th. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $9.75.
About Ziopharm Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.
Receive News & Ratings for Ziopharm Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.